Showing results (121-130 of 131) with videos related to
Sort By:
Pageof 14
Iscience|April 25, 2025
Erratum: JUN mediates glucocorticoid resistance by stabilizing HIF1a in T cell acute lymphoblastic leukemiaZhijie Zhang, Jiangzhou Shi, Qifang Wu, et al.Signal Transduction and Targeted Therapy|April 11, 2022
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCTJia Wei, Min Xiao, Zekai Mao, et al.International Journal of Molecular Sciences|January 28, 2026
Upregulation of the TCA Cycle and Oxidative Phosphorylation Enhances the Fitness of CD99 CAR-T Cells Under Dynamic CultivationJiaxuan Zhao, Youyong Wang, Yixuan Wang, et al.Journal of Hematology & Oncology|October 10, 2021
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicityJiangzhou Shi, Zijian Zhang, Hong Cen, et al.Scientific Reports|June 21, 2022
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activityShangkun Zhang, Chaojiang Gu, Lifang Huang, et al.Transplantation and Cellular Therapy|August 23, 2021
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell LymphomasYang Cao, Yi Xiao, Na Wang, et al.Frontiers in Immunology|June 7, 2022
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt LymphomaJiaying Wu, Yang Cao, Qi Zhang, et al.Nature Biomedical Engineering|September 11, 2023
Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogelXianlei Li, Ningqiang Gong, Falin Tian, et al.Blood|November 8, 2019
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignanciesNa Wang, Xuelian Hu, Wenyue Cao, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2025
Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapyJie Shi, Zijian Zhang, Hsin-Yi Chen, et al.Pageof 14